Transthyretin Cardiac Amyloidosis: Pathogenesis, Treatments, and Emerging Role in Heart Failure with Preserved Ejection Fraction
Transthyretin (TTR) amyloidosis causes heart failure from cardiac deposition of TTR amyloid fibrils, the by-product of TTR homotetramer disassembly. Wild-type (WT) TTR deposition leads to senile amyloidosis, predominantly manifesting with cardiomyopathy. Missense mutations in the TTR gene result in...
Main Authors: | Van-Khue Ton, Monica Mukherjee, Daniel P. Judge |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2014-01-01
|
Series: | Clinical Medicine Insights: Cardiology |
Online Access: | https://doi.org/10.4137/CMC.S15719 |
Similar Items
-
Transthyretin Cardiac Amyloidosis: Pathogenesis, Treatments, and Emerging Role in Heart Failure with Preserved Ejection Fraction
by: Van-Khue Ton, et al.
Published: (2015-01-01) -
Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
by: Sebastiaan HC Klaassen, et al.
Published: (2020-08-01) -
Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan
by: Takanori Naito, et al.
Published: (2023-06-01) -
Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure
by: Gabriela Molina O, et al.
Published: (2014-11-01) -
Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction
by: Evandro Tinoco Mesquita, et al.